SARS-CoV-2 Controls
cfDNA Pan-cancer
- What is your background cfDNA made from?
- Were the mutations in the standards confirmed by NGS as well, as with digital PCR as it says in the document?
- Variant (COSM214499) is always high in 0% in NGS QC results, why?
- Are there different needs between amplicon and hybrid capture customers?
- Do you recommend to pool this control with patient sample after library prep, before NGS?
- What reagents (e.g., library prep) do you use for the liquid biopsy workflow?
- Can’t find indel or other hard to detect variants?
- What is the recommend input and dilution buffer?
- How do we know we are very close to natural background cfDNA?
- What is the WGS and WES setting to qualify the cfDNA material, and QC the Twist cfDNA?
- Is your background cfDNA limited supply?
- What is the structure of the 3' and 5'?
- How do you design the ctDNA/ variant list?
- Is there any concern for introduced bias for the expansion of cfDNA?
- Do you shear donor derived background?
- Does your product have matrics (e.g., synthetic plasma, plasma)?
- Are these control oligos, RNA, what is in it/ components?
- Is background cfDNA from a mixed pool of donors?
- For NGS QC, do you use target capture sequence for the 458 variants or use a whole genome sequence?
